Olaparib Sustained Release Composition for Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The immediate release preparation of olaparib experiences severe plasma concentration peak and valley fluctuations, leading to dose-limiting toxicity, low bioavailability, and inconvenient clinical administration, requiring high doses and causing significant side effects due to rapid elimination and poor absorption.
Innovation Solution
An oral sustained and controlled release pharmaceutical composition of olaparib is developed, utilizing an improved dissolution form such as olaparib salt, co-grinding mixture, nanocrystal, or solid dispersion combined with a release rate adjusting matrix polymer like cellulose derivatives or starch, to control absorption and maintain effective plasma concentrations for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release preparation is used, then rapid plasma concentration peak is achieved, but severe plasma concentration fluctuations and dose-limiting toxicity occur
Solution Approach 1:
The patent transforms the static immediate-release formulation into a dynamic controlled-release system that adapts drug release to physiological conditions. The composition uses multiple polymers with different release characteristics to dynamically regulate plasma concentration, preventing both peak toxicity and subtherapeutic troughs while maintaining sustained effective levels throughout the dosing interval.
Solution Approach 2:
The patent changes the release rate parameter of olaparib from rapid (immediate release) to controlled and sustained. By incorporating specific polymer ratios and dissolution-modified olaparib forms, the system alters the kinetic parameters of drug release, achieving a flattened concentration-time profile that maintains levels within the therapeutic window without exceeding toxic thresholds.
2Reliability
If high dose is administered to maintain plasma concentration above IC90, then enzyme inhibition effect is enhanced, but toxic side effects increase
Solution Approach 1:
The patent ensures continuous therapeutic action by designing a controlled-release formulation that maintains olaparib plasma concentrations above the IC90 threshold for PARP inhibition throughout the entire dosing interval. The sustained release mechanism prevents concentration drops below effective levels, ensuring uninterrupted enzyme inhibition and consistent antitumor activity without requiring dose escalation that would increase toxicity.
Solution Approach 2:
The patent introduces polymer matrices and dissolution-modified olaparib forms as intermediary substances that mediate between the administered dose and the active drug at the target site. These intermediaries control the rate and pattern of drug release, allowing maintenance of effective concentrations through lower total doses by optimizing the time-profile of drug availability rather than relying on high peak concentrations.
3Reliability
If multiple daily administrations are required, then plasma concentration can be maintained, but patient compliance deteriorates
Solution Approach 1:
The patent employs extended-release polymers that continue releasing drug beyond the typical dosing interval, providing partial coverage into the next dosing period. This excessive release action ensures that even with once-daily or twice-daily dosing, plasma concentrations remain above the IC90 threshold throughout the interval, maintaining reliable enzyme inhibition while reducing administration frequency and improving patient compliance.
4Speed
If olaparib is rapidly eliminated, then short half-life is achieved, but frequent dosing is required
Solution Approach 1:
The patent applies preliminary action by incorporating drug reservoirs and controlled-release matrices that begin releasing olaparib before plasma concentrations would naturally decline. The formulation pre-establishes a sustained release mechanism that compensates for rapid elimination, extending the effective dosing interval without requiring changes to the drug's intrinsic pharmacokinetic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This composition achieves controlled release of olaparib, reducing toxic side effects, improving bioavailability, and allowing for lower doses with more stable plasma concentrations, enhancing therapeutic efficacy while minimizing tablet or capsule size and frequency, thus improving patient compliance and treatment convenience.
Implementation Method 1
a release rate adjusting matrix polymer like cellulose derivatives or starch, to control absorption and maintain effective plasma concentrations for extended periods
Implementation Method 2
utilizing an improved dissolution form such as olaparib salt, co-grinding mixture, nanocrystal, or solid dispersion combined with a release rate adjusting matrix polymer
Data Source
Figure 1~7
Figure 8~9
Figure 10~11
AI summary
An olaparib oral sustained and controlled release pharmaceutical composition contains an olaparib in an improved dissolution form and a release rate adjusting matrix polymer. The pharmaceutical composition has controllable in-vivo absorption behavior, plasma concentration and PARP enzyme inhibition level, and improved drug load and/or oral absorption and/or bioavailability and/or plasma concentration control and/or enzyme inhibition level control of olaparib, and can be used as the only preparation or in combination with other therapies to treat a cancer.